DXCMDexcom
$79.41+16% 1Y
$79.41
$54.8452 weeks$92.35
What has happened
DXCM in its own filings
Nothing in DXCM's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.
409
Events found in the filings · across 2,651 filings · the record starts in 2005
- Hard flags
- none
Hard flags
- Most recent filing
- Oct 29, 2026
Most recent filing · Form 10-Q
- Record starts
- Feb 25, 2005
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Feb 11, 2027
- Change in certifying accountantpast_3y
- 2025-03-25
- SEC comment-letter activity18 occurrences
- 2022-05-05
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Earnings release
On October 29, 2026, Dexcom announced that its Board of Directors authorized and approved a share repurchase program of up to $1.0 billion of Dexcom’s outstanding common stock, par value $0.001 per share (“Common Stock”), with a repurchase period ending no later than December 31, 2027 (the “Share Repurchase Program”)
Form 8-K on sec.gov ↗ - Director or officer change
On September 10, 2026, the Board of Directors (the “Board”) of DexCom, Inc. (“Dexcom” or the “Company”) appointed Jereme Sylvain, the Company’s EVP, Chief Financial Officer, to the role of EVP, Chief Operating Officer and Chief Financial Officer, effective September 14, 2026.
Form 8-K on sec.gov ↗ - Director or officer change
On September 10, 2026, the Board of Directors (the “Board”) of DexCom, Inc. (“Dexcom” or the “Company”), pursuant to the Amended and Restated Bylaws of the Company, increased the size of the Board to thirteen directors and appointed Glenn S. Boehnlein as a director, effective immediately.
Form 8-K on sec.gov ↗
Earlier reports (8)›
- Regulation FD disclosure
On May 14, 2026, Dexcom announced that its Board of Directors authorized and approved a share repurchase program of up to $1.0 billion of Dexcom’s outstanding common stock, par value $0.001 per share (“Common Stock”), with a repurchase period ending no later than June 30, 2027 (the “Share Repurchase Program”)
Form 8-K on sec.gov ↗ - Director or officer change
As previously reported on the Current Report on Form 8-K filed on July 30, 2025, Kevin R. Sayer notified the Board of Directors (the “Board”) of DexCom, Inc. (“Dexcom” or the “Company”) of his intent to retire from his role as Chief Executive Officer effective January 1, 2026.
Form 8-K on sec.gov ↗ - Director or officer change
On February 26, 2026, the Board of Directors (the “Board”) of DexCom, Inc. (“Dexcom” or the “Company”), pursuant to the Amended and Restated Bylaws of the Company, increased the size of the Board to twelve directors and appointed Albert F. (“Rick”) Osterloh, IV as a director effective immediately.
Form 8-K on sec.gov ↗ - Earnings release
Dexcom Reports Fourth Quarter and Fiscal Year 2025 Financial Results.
The press release on sec.gov ↗ - Earnings release
Dexcom Enters Next Era of Continued Innovation with Jake Leach as President and Chief Executive Officer.
The press release on sec.gov ↗ - Director or officer change
As previously reported on the Current Report on Form 8-K filed on July 30, 2025, the Board of Directors (the “Board”) of DexCom, Inc. (“Dexcom” or the “Company”) appointed Jacob S. Leach, President and Chief Operating Officer, as the President and Chief Executive Officer and as a director of the Company, effective …
Form 8-K on sec.gov ↗
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…
Medical Devices
The closest names by size in the same industry